Concepedia

Michel Friesenhahn

MF

16

Publications

1.3K

Citations

16

H-Index

2000

Active since

Affiliations

Bayer (United States)(Current)

Cleveland Clinic

Lou Ruvo Brain Institute

Gene Therapy Laboratory

BC Centre for Disease Control

Michel Friesenhahn is an author at Bayer (United States) specializing in medicine, neurology, and pharmacotherapy.

Top concepts

Publications per year

2000–2022

16

Publications

16

An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A  Binding Properties Promotes Neuroprotection and Glial Engulfment of A 

Oskar Adolfsson, Maria Pihlgren, Nicolas Toni et al. · Journal of Neuroscience · 2012 · 296 citations · Full text

ABBY

Jeffrey L. Cummings, Sharon Cohen, Christopher H. van Dyck et al. · Neurology · 2018 · 247 citations · Full text

Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging

James P.B. O’Connor, Richard A.D. Carano, Andrew R. Clamp et al. · Clinical Cancer Research · 2009 · 158 citations · Full text

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)

Stephen Salloway, Lee Honigberg, Michael E. Ward et al. · Alzheimer s Research & Therapy · 2018 · 149 citations · Full text

Clinical performance and robustness evaluation of plasma amyloid‐β<sub>42/40</sub> prescreening

Christina Rabe, Tobias Bittner, Alexander Jethwa et al. · Alzheimer s & Dementia · 2022 · 79 citations · Full text

, , +15

Rows per page

1–5 of 16